Benitec Biopharma Inc. (BNTC)
NASDAQ: BNTC · Real-Time Price · USD
12.88
-0.14 (-1.08%)
At close: Aug 26, 2026, 4:00 PM EDT
12.85
-0.03 (-0.23%)
After-hours: Aug 26, 2026, 7:30 PM EDT
Benitec Biopharma Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
19
Market Cap
442.48M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | - | - | - |
| Jun 30, 2024 | - | - | - |
| Jun 30, 2023 | 75.00K | 2.00K | 2.74% |
| Jun 30, 2022 | 73.00K | 14.00K | 23.73% |
| Jun 30, 2021 | 59.00K | -43.00K | -42.16% |
| Jun 30, 2020 | 102.00K | -12.10M | -99.16% |
| Jun 30, 2019 | 12.20M | 8.81M | 259.85% |
| Jun 30, 2018 | 3.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 231.24M |
| vTv Therapeutics | 36.84M |
| Arcturus Therapeutics Holdings | 29.37M |
| Ocugen | 4.58M |
| EyePoint | 2.79M |
| Compass Therapeutics | 850.00K |
| Inhibikase Therapeutics | 1.00 |
BNTC News
- 4 weeks ago - Wedbush bullish on Benitec Biopharma, initiates with an Outperform - TheFly
- 4 weeks ago - Benitec Biopharma initiated with an Outperform at Wedbush - TheFly
- 2 months ago - Guggenheim downgrades Benitec to Neutral, terminates coverage - TheFly
- 2 months ago - Benitec Biopharma downgraded to Neutral from Buy at Guggenheim - TheFly
- 3 months ago - Benitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational Update - GlobeNewsWire
- 3 months ago - Benitec Biopharma Earnings release: Q3 2026 - Filings
- 3 months ago - Benitec Biopharma Quarterly report: Q3 2026 - Filings
- 3 months ago - Benitec Biopharma initiated with an Outperform at Evercore ISI - TheFly